CROs And Biopharma Weigh The Balance Of Risk And Responsibility
Executive Summary
Biopharmaceutical companies have been outsourcing R&D activity to CROs for a while, but neither they nor CROs have sorted out which side should bear the burden of what kind of risk and how to best structure operations.
You may also be interested in...
Clinical Data In 2014 Could Trigger Private Biotech Financings
Despite difficulties financing late-stage trials, several private companies are expecting Phase II and III data that should help shape public investor sentiment this year. Familiar compounds in new guises lead the way.
J.P. Morgan Notebook: Thursday, January 16
News and notes from the fourth and final day of the 2014 J.P. Morgan Healthcare Conference, including highlights from Furiex Pharmaceuticals’ late-stage pipeline, GSK’s latest DPU, newly public Intrexon, and angel-backed KemPharm.